Research programme: bacterial and fungal vaccines - NovaDigm Therapeutics

Drug Profile

Research programme: bacterial and fungal vaccines - NovaDigm Therapeutics

Alternative Names: Candida vaccines - NovaDigm Therapeutics; Meticillin-resistant Staphylococcus aureus vaccine - NovaDigm Therapeutics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaDigm Therapeutics
  • Class Bacterial vaccines; Fungal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Candidiasis; Staphylococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Parenteral)
  • 01 Dec 2008 Preclinical trials in Candidiasis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top